[HTML][HTML] Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer
A Okita, S Takahashi, K Ouchi, M Inoue, M Watanabe… - Oncotarget, 2018 - ncbi.nlm.nih.gov
The consensus molecular subtypes (CMS) classification is one of the most robust colorectal
cancer (CRC) classifications based on comprehensive gene expression profiles. This study …
cancer (CRC) classifications based on comprehensive gene expression profiles. This study …
[HTML][HTML] The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular …
Background The consensus molecular subtypes (CMS) is a transcriptome-based
classification of colorectal cancer (CRC) initially described in early-stage cohorts, but the …
classification of colorectal cancer (CRC) initially described in early-stage cohorts, but the …
Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance)
PURPOSE To determine the predictive and prognostic value of the consensus molecular
subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression …
subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression …
Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis
S Ten Hoorn, TR de Back… - JNCI: Journal of the …, 2022 - academic.oup.com
Background The consensus molecular subtypes (CMSs) of colorectal cancer (CRC) capture
tumor heterogeneity at the gene-expression level. Currently, a restricted number of …
tumor heterogeneity at the gene-expression level. Currently, a restricted number of …
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) …
3511 Background: CALGB 80405 was a randomized Ph3 trial showing no OS or PFS
difference in mCRC pts treated with Bevacizumab (BV) or Cetuximab (Cet) in the first line. A …
difference in mCRC pts treated with Bevacizumab (BV) or Cetuximab (Cet) in the first line. A …
[HTML][HTML] Consensus molecular subtypes of colorectal cancer in clinical practice: a translational approach
G Valenzuela, J Canepa, C Simonetti… - World Journal of …, 2021 - ncbi.nlm.nih.gov
The identification of several genetic mutations in colorectal cancer (CRC) has allowed a
better comprehension of the prognosis and response to different antineoplastic treatments …
better comprehension of the prognosis and response to different antineoplastic treatments …
Investigation of colorectal cancer in accordance with consensus molecular subtype classification
H Sawayama, Y Miyamoto, K Ogawa… - Annals of …, 2020 - Wiley Online Library
The classification of colorectal cancer (CRC) plays a pivotal role in predicting a patient's
prognosis and determining treatment strategies. The consensus molecular subtype (CMS) …
prognosis and determining treatment strategies. The consensus molecular subtype (CMS) …
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
PW Eide, SH Moosavi, IA Eilertsen, TH Brunsell… - NPJ genomic …, 2021 - nature.com
Gene expression-based subtypes of colorectal cancer have clinical relevance, but the
representativeness of primary tumors and the consensus molecular subtypes (CMS) for …
representativeness of primary tumors and the consensus molecular subtypes (CMS) for …
Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide.
Similar to many other malignancies, CRC is a heterogeneous disease, making it a clinical …
Similar to many other malignancies, CRC is a heterogeneous disease, making it a clinical …
[HTML][HTML] Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
M Del Rio, C Mollevi, F Bibeau, N Vie, J Selves… - European Journal of …, 2017 - Elsevier
Background Currently, metastatic colorectal cancer is treated as a homogeneous disease
and only RAS mutational status has been approved as a negative predictive factor in …
and only RAS mutational status has been approved as a negative predictive factor in …
相关搜索
- predictive factor colorectal cancer
- predictive factor chemotherapeutic efficacy
- chemotherapeutic efficacy colorectal cancer
- metastatic heterogeneity colorectal cancer
- molecular subtyping colorectal cancer
- meta analysis colorectal cancer
- molecular subtypes patient response
- cetuximab or bevacizumab colorectal cancer
- clinical value colorectal cancer
- clinical practice colorectal cancer